AdvaMed To Seek Legislative Fix To Ease New Tech Add-On Payment Criteria

CMS' discovery that Stryker Biotech (OP-1) has offered a comparable product to Medtronic's InFuse bone graft for tibia fractures since 2001 led the agency to reject the latter firm's new technology add-on application